Drug Profile

GRWD 0715

Alternative Names: GRWD-0715

Latest Information Update: 10 Sep 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Grey Wolf Therapeutics
Class Anti-inflammatories; Antirheumatics; Small molecules
Mechanism of Action ERAP1 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase I/II Axial spondyloarthritis
Preclinical Autoimmune disorders

Most Recent Events

08 Sep 2026 Grey Wolf Therapeutics has patent protection for GRWD 0715 in USA
08 Sep 2026 Grey Wolf Therapeutics plans a phase IIa proof of concept trial for Axial spondyloarthritis in second half of 2027
28 Jul 2025 Phase-I/II clinical trials in Axial spondyloarthritis (Treatment-experienced) in Poland, Netherlands, Germany, Belgium (PO) (NCT07047703)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com